Journal
LANCET PUBLIC HEALTH
Volume 6, Issue 5, Pages E335-E345Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S2468-2667(21)00055-4
Keywords
-
Categories
Funding
- Medical Research Council (MRC), UK Research & Innovation (UKRI)
- UK National Institute for Health Research (NIHR)
- Genome Research (operating as the Wellcome Sanger Institute)
- NIHR-funded Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- Wellcome Trust [212904/Z/18/Z, WT203148/Z/16/Z]
- MRC
- British Heart Foundation [MR/M016560/1]
- Alzheimer's Society
- EU
- NIHR
- Chronic Disease Research Foundation
- NIHR-funded BioResource, Clinical Research Facility, and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with Kings College London
- UKRI London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare
- Wellcome Flagship Programme [WT213038/Z/18/Z]
- Department of Health and Social Care
- Stuart and Suzanne Steele Massachusetts General Hospital Research Scholar Award
- Massachusetts Consortium on Pathogen Readiness and Mark and Lisa Schwartz
Ask authors/readers for more resources
The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.
Background The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. We aimed to investigate whether increases in the proportion of infections with this variant are associated with differences in symptoms or disease course, reinfection rates, or transmissibility. Methods We did an ecological study to examine the association between the regional proportion of infections with the SARS-CoV-2 B.1.1.7 variant and reported symptoms, disease course, rates of reinfection, and transmissibility. Data on types and duration of symptoms were obtained from longitudinal reports from users of the COVID Symptom Study app who reported a positive test for COVID-19 between Sept 28 and Dec 27, 2020 (during which the prevalence of B.1.1.7 increased most notably in parts of the UK). From this dataset, we also estimated the frequency of possible reinfection, defined as the presence of two reported positive tests separated by more than 90 days with a period of reporting no symptoms for more than 7 days before the second positive test. The proportion of SARS-CoV-2 infections with the B.1.1.7 variant across the UK was estimated with use of genomic data from the COVID-19 Genomics UK Consortium and data from Public Health England on spike-gene target failure (a non-specific indicator of the B.1.1.7 variant) in community cases in England. We used linear regression to examine the association between reported symptoms and proportion of B.1.1.7. We assessed the Spearman correlation between the proportion of B.1.1.7 cases and number of reinfections over time, and between the number of positive tests and reinfections. We estimated incidence for B.1.1.7 and previous variants, and compared the effective reproduction number, R-t, for the two incidence estimates. Findings From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7. For the same period, possible reinfections were identified in 249 (0.7% [95% CI 0.6-0.8]) of 36 509 app users who reported a positive swab test before Oct 1, 2020, but there was no evidence that the frequency of reinfections was higher for the B.1.1.7 variant than for pre-existing variants. Reinfection occurrences were more positively correlated with the overall regional rise in cases (Spearman correlation 0.56-0.69 for South East, London, and East of England) than with the regional increase in the proportion of infections with the B.1.1.7 variant (Spearman correlation 0.38-0.56 in the same regions), suggesting B.1.1.7 does not substantially alter the risk of reinfection. We found a multiplicative increase in the R-t of B.1.1.7 by a factor of 1.35 (95% CI 1.02-1.69) relative to pre-existing variants. However, R-t fell below 1 during regional and national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant. Interpretation The lack of change in symptoms identified in this study indicates that existing testing and surveillance infrastructure do not need to change specifically for the B.1.1.7 variant. In addition, given that there was no apparent increase in the reinfection rate, vaccines are likely to remain effective against the B.1.1.7 variant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available